haarlemsdagblad

Part of evidence against US insurance executive murder suspect ruled illegal

Part of evidence against US insurance executive murder suspect ruled illegal

A New York judge has ruled that some evidence against Luigi Mangione, the suspect in the murder of UnitedHealthcare CEO Brian Thompson, is inadmissible because it was obtained illegally. Mangione is accused of killing Thompson in late 2024, and his trial is scheduled to begin on September 8.

Related articles

Blockade of Strait of Hormuz could lead to global recession

Blockade of Strait of Hormuz could lead to global recession

The global economy risks a recession if the Strait of Hormuz remains closed due to ongoing tensions between Iran and the United States. This situation threatens to increase costs for consumers in the Netherlands and across Europe, impacting both fuel prices and grocery expenses.

Chip stocks recover on stock market after weeks of heavy losses

Chip stocks recover on stock market after weeks of heavy losses

Chip companies Besi, ASMI, and ASML saw a strong recovery on the stock market on Tuesday following several weeks of significant losses. This upward trend in technology stocks was also observed across the rest of Europe and on Wall Street.

Trio suspected of kidnapping and extorting four men

Trio suspected of kidnapping and extorting four men

Three men appeared in court on suspicion of kidnapping and extorting four victims by forcing them to withdraw cash at ATM machines. While one suspect will await his trial outside of prison, two brothers remain in custody for the incidents, which involved threats and alleged false claims of membership in the Satudarah motorcycle club.

Swiss grounds two pilots for drinking before flight

Swiss grounds two pilots for drinking before flight

Swiss International Air Lines has suspended two pilots after they were found to be under the influence of alcohol before a flight from Geneva earlier this year. The airline confirmed the disciplinary action on Tuesday.

Novo Nordisk sues competitor Eli Lilly over misleading advertising

Novo Nordisk sues competitor Eli Lilly over misleading advertising

Danish pharmaceutical company Novo Nordisk has filed a lawsuit in the United States against its competitor Eli Lilly. The company alleges that Eli Lilly's advertisements for the weight-loss injection Zepbound and the diabetes medication Mounjaro are misleading.